BusinessStory of Traumatic Brain Injury Wins #IAmInvisibleNoMore Video ContestBy Nasdaq OMXMay 4, 2018, 9:10 PM UTC
BusinessAxsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical TrialBy Nasdaq OMXJul 25, 2017, 11:01 AM UTC
BusinessFlexion Therapeutics Announces Presentation of Results From Pivotal Phase 2b and Phase 3 Clinical Trials for Zilretta™ at Osteoarthritis Research Society International (OARSI) 2016 World CongressBy Nasdaq OMXApr 4, 2016, 11:00 AM UTC
BusinessFlexion Therapeutics Reports Primary Endpoint Met in Pivotal Phase 3 Trial of Zilretta™ in Knee OsteoarthritisBy Nasdaq OMXFeb 16, 2016, 9:01 PM UTC
BusinessAxsome Therapeutics Announces Issuance of U.S. Patent Covering AXS-02 for the Treatment of Bone Marrow Lesions of the KneeBy Nasdaq OMXJan 27, 2016, 11:30 AM UTC
BusinessFlexion Therapeutics to Present at Oppenheimer 26th Annual Healthcare ConferenceBy Nasdaq OMXDec 4, 2015, 1:00 PM UTC
BusinessFlexion Therapeutics Enrolls First Patient in Pharmacokinetic Study of Zilretta™ for Osteoarthritis of the KneeBy Nasdaq OMXDec 1, 2015, 9:05 PM UTC
